You can now read 10 articles each month for free on BostonGlobe.com.

The Boston Globe

Business

market mover

Vivus shares surge as FDA approves weight-loss drug

Consumers can soon choose between Vivus’s new drug and Belviq, from Arena Pharmaceuticals and Eisai Co. The pills are the first approved for obesity since 1999.

jewel samad/AFP/Getty Images/File 2011

Consumers can soon choose between Vivus’s new drug and Belviq, from Arena Pharmaceuticals and Eisai Co. The pills are the first approved for obesity since 1999.

Continue reading below

Vivus Inc. rose the most in
almost four months after winning approval from US regulators for its obesity drug, Qsymia. Vivus plans to begin selling Qsymia in the fourth quarter, with a warning about potential heart and birth-defect risks. It may generate $1.2 billion in sales in 2016, according to the average of five analysts’ estimates.

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week